Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 9, 2012, Pages 1057-1069

  Bernard, Apexa ^a,b   Kimko, Holly ^a   Mital, Dinesh ^b   Poggesi, Italo ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Cancer; Mathematical models; Model Based Drug Development (MBDD); Oncology drug development; Pharmacokineticpharmacodynamic models

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; MOTESANIB; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CALCULATION; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESEARCH; HUMAN; LUNG NON SMALL CELL CANCER; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; REVIEW; SIMULATION; THYROID CANCER; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; EMPIRICAL RESEARCH; ENDPOINT DETERMINATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RESEARCH DESIGN;

EID: 84865328468     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.693480     Document Type: Review

References (73)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-16
2. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff 2006;25:420-8 (Pubitemid 43529550)
3. Cockburn IM. Is the pharmaceutical industry in a productivity crisis? In: Lerner J, Stern S, editors. Innovation policy and the economy. Volume 7, MIT Press, Cambridge, MA; 2007
4. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. Food and drug administration, March 2004. Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf [Last accessed 28 Dec 2011]
5. Shepard T. Role of modelling and simulation in regulatory decision making in Europe. EMA-EFPIA Modelling and Simulation Workshop, London 2011. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/Presentation/2011/ 11/WC500118262.pdf [Last accessed 28 Dec 2011]
6. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther 2007;82:21-32 (Pubitemid 46950619)
7. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J 2008;10:552-9
8. Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov 2007;2:185-209 (Pubitemid 47073087)
9. Nucci G, Gomeni R, Poggesi I. Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity. Expert Opin Drug Discov 2009;4:837-85
10. Santen G, van Zwet E, Danhof M, Della Pasqua O. From trial and error to trial simulation. Part 1: the importance of model-based drug development for antidepressant drugs. Clin Pharmacol Ther 2009;86:248-54
11. Santen G, Horrigan J, Danhof M, Della Pasqua O. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. Clin Pharmacol Ther 2009;86:255-62
12. Samtani MN, Farnum M, Lobanov V, et al. An improved model for disease progression in patients from the Alzheimer's Disease neuroimaging initiative. J Clin Pharmacol 2011;published online 9 June 2011; DOI: 10.1177/0091270011405497.
13. Kimko HHC, Peck CC, editors. Clinical trial simulations. Applications and trends. AAPS Press, New York; 2011
14. Zhou Q, Gallo JM. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. AAPS J 2011;13:111-20
15. Sanga S, Frieboes HB, Zheng X, et al. Predictive oncology: multidisciplinary, multi-scale in-silico modeling linking phenotype, morphology and growth. Neuroimage 2007;37(Suppl 1):S120-34 (Pubitemid 47239436)
16. Della Pasqua O. PKPD and disease modeling: concepts and applications to oncology. In: Kimko HHC, Peck CC, editors. Clinical trial simulations. Applications and trends. AAPS Press, New York; 2011
17. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003;2:131-8
18. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10:514-23
19. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer 2008;44:142-50 (Pubitemid 350256941)
20. Yamazaki S, Skaptason J, Romero D, et al. Pharmacokinetic-Pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008;36:1267-74 (Pubitemid 351929310)
21. Yamazaki S, Nguyen L, Vekich S, et al. Pharmacokinetic-Pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available Heat Shock Protein 90 inhibitor in a human tumor xenograft mouse model. JPET 2011;338:964-73
22. Salphati L, Wong H, Belvin M, et al. Pharmacokinetic-Pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 2010;38:1436-42
23. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12:7180-6 (Pubitemid 44974520)
24. Claret L, Girard P, Hoff PM, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009;27:4103-8
25. Claret L, Lu J-F, Sun Y-N, Bruno R. Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol 2010;66:1141-9
26. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009;86:167-74
27. Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst 2008;100:1500-10
28. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2008;7:645-58 (Pubitemid 47327410)
29. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 2004;40:827-36 (Pubitemid 38519761)
30. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005;205:194-205 (Pubitemid 40227991)
31. Voscoglu-Nomikos T, Pater JL, Seymour L. Clinical predictive value of in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39 (Pubitemid 37204044)
32. Poggesi I, De Nicolao G, Germani M, Rocchetti M. Re: antitumor efficacy testing in rodents. J Natl Cancer Inst 2009;101:1592-3
33. Rocchetti M, Simeoni M, Pesenti E, et al. Predicting the active doses in humans from animal studies: a novel approach in oncology. Eur J Cancer 2007;12:1862-8 (Pubitemid 47243652)
34. Wong H, Choo EF, Alicke B, et al. Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: a pharmacokinetic-pharmacodynamic analysis. Mol Cancer Ther 2011;10(Suppl 1):abstract TARG-11-A11-AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 12-16 Nov 2011; San Francisco, CA
35. Gorelik B, Ziv I, Shohat R, et al. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 2008;68:9033-40
36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16 (Pubitemid 30099779)
37. Aarons L, Ogungbenro K. Optimal design of pharmacokinetic studies. Basic Clin Pharmacol Toxicol 2010;106:250-5
38. Bajzer Z, Marusic M, Vuk-Pavlovic S. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math Comput Model 1996;23:31-46 (Pubitemid 126686207)
39. Nestorov I, Rowland M, Hadjitodorov ST, Petrov I. Empirical versus mechanistic modelling: comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetic relationships of a homologous series of barbiturates. AAPS PharmSci 1999;1(article 17):1-9
40. Skipper HE, Schabel FM Jr, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-50
41. Porrata LF, Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumors. Br J Cancer 2001;85:484-9 (Pubitemid 32808268)
42. Norton L, Hudis C. Role of modeling in pharmacotherapeutics. In: Piccart M, Wood WC, Hung M-C, Solin LJ, Cardosa F, editors. Breast cancer and molecular medicine. Springer-Verlag Berlin; Heidelberg: 2006
43. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001;6:30-5 (Pubitemid 32423184)
44. Jusko WJ. Pharmacodynamics of therapeutic effects: dose-time relationships for phase nonspecific agents. J Pharm Sci 1971;60:892-5
45. Jusko WJ. A pharmacodynamic model for cell-cycle specific chemotherapeutic agents. J Pharmacokinet Pharmacodyn 1973;1:175-200
46. Goldie JH, Coldman A. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-53 (Pubitemid 14041569)
47. DeVita VT Jr, Chu E. Biology of drug resistance. DeVita, Hellman, and Rosenberg's Cancer: principles & practice of oncology. 8th edition. Lippincott Williams & Wilkins, Philadelphia, PA; 2008
48. Teicher B. Tumor models for efficacy determination. Mol Cancer Ther 2006;5:2435-43 (Pubitemid 44650906)
49. Creton G, Benassi MI, Di Staso M, et al. The time factor in oncology: consequences of tumour volume and therapeutic planning. J Exp Clin Cancer Res 2006;25:557-73 (Pubitemid 46166771)
50. Verhulst P-F. Notice sur la loi que la population poursuit dans son accroissement. Correspondance Mathematique et Physique 1838;10:113-21
51. Gonze D. The logistic equation. Available from: http://homepages.ulb.ac. be/~dgonze/TEACHING/logistic.pdf [Last accessed 28 Feb 2012]
52. Von Bertalanffy L. Untersuchungen uber die Gesetzlichkeit des Wachstums. I. Allgemeine Grundlagen der Theorie; mathematische und physiologische Gesetzlichkeiten des Wachstums bei Wassertieren. Arch Entwicklungsmech 1934;131:613-52
53. Laird AK. Dynamics of tumor growth. Br J Cancer 1964;18:490-502
54. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005;10:370-81
55. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-9 (Pubitemid 16140378)
56. Traina T, Dugan U, Higgins B, et al. Optimizing chemotherapy dose and schedule by norton-simon mathematical modeling. Breast Dis 2010;31:7-18
57. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9 (Pubitemid 46594092)
58. Lobo ED, Balthasar JP. Pharmacodynamic modeling of chemotherapeutic effects: application of transit compartmental model to characterize methotrexate effects in vitro. AAPS J 2002;4(article 42):1-11
59. Yang J, Mager DE, Straubinger RM. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J 2010;12:1-10
60. Simeoni M, Magni P, Cammia C, et al. Predictive pharmacokinetic- pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004;64:1094-101 (Pubitemid 38176915)
61. Magni P, Germani M, De Nicolao G, et al. A minimal model of tumor growth inhibition. IEEE Trans Biomed Engineer 2008;55:2683-90
62. Jumbe NL, Xin Y, Leipold DD, et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 2010;37:221-42
63. Danhof M, Alvan G, Dahl SG, et al. Mechanism-based pharmacokinetic- pharmacodynamic modeling - a new classification of biomarkers. Pharm Res 2005;22:1432-7 (Pubitemid 41215882)
64. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34:607-15 (Pubitemid 46364019)
65. Therasse P. Evaluation of response: new and standard criteria. Ann Oncol 2002;13(Suppl 4):127-9 (Pubitemid 35363763)
66. Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14 (Pubitemid 11167383)
67. Lu J-F, Claret L, Sutjandra L, et al. Population pharmacokinetic/ pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol 2010;66:1151-8
68. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010;66:357-71
69. An M-W, Mandrekar SJ, Branda ME, et al. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 2011;17:6592-9
70. Tham L-S, Wang L, Soo RA, et al. A pharmacodynamic model for the time course of tumor shrinkage by gemcytabine + carboplatin in non-small cell lung cancer patients. Clin cancer Res 2008;14:4213-18
71. Bonate PL. Modeling tumor growth in oncology. In: Bonate PL, Howard DR, editors. Pharmacokinetics in drug development. AAPS Press, New York; 2011
72. Zhang L, Allerheiligen SR, Lalonde RL, et al. Fostering culture and optimizing organizational structure for implementing model-based drug development. J Clin Pharmacol 2010;50:146S-50S
73. Wetherington JD, Pfister M, Banfield C, et al. Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol 2010;50:31S-46S